This week, the Food and Drug Administration approved Johnson & Johnson’s Spravato, the nasal spray version of a ketamine-like sedative, for certain cases of depression. And the drug is already being heralded as a “game-changer” for depression and suicide treatment. But chief among the major questions the average…
